Phase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.
Trial locations(10 sites)
United States
Cedars Sinai Medical Center, Los Angeles, California Sarah Cannon Research Institute at HealthOne, Denver, Colorado Northwestern Medicine Cancer Center, Chicago, Illinois Ohio State University, Columbus, Ohio SCRI Oncology Partners, Nashville, Tennessee Vanderbilt-Ingram Cancer Center, Nashville, Tennessee MD Anderson Cancer Center, Houston, Texas University of Washington, Seattle, Washington Japan
National Cancer Center Hospital East, Kashiwa-shi Kyoto University Hospital, Kyoto